Limb Girdle Muscular Dystrophy (LGMD) Market Insights, Epidemiology and Market Forecast - 2028

Publisher Name :
Date: 15-Apr-2019
No. of pages: 100
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's Limb Girdle Muscular Dystrophy (LGMD)-Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Limb Girdle Muscular Dystrophy (LGMD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Limb Girdle Muscular Dystrophy (LGMD) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

- The United States

- EU5 (Germany, France, Italy, Spain and the United Kingdom)

- Japan

Study Period: 2017-2028

Limb Girdle Muscular Dystrophy (LGMD) - Disease Understanding and Treatment Algorithm

Limb-Girdle Muscular Dystrophy (LGMD) encompasses heterogeneous group of rare, genetic, degenerative muscle disorders; with both childhood and adult-onset dystrophy. It is a genetically inherited condition that primarily affects skeletal muscle leading to progressive, predominantly proximal muscle weakness at presentation caused by a loss of muscle fibers. It is generally characterized by weakness of the shoulder and the pelvic girdle muscles. The mutations in genes leads to the loss of various proteins that are involved in muscle maintenance and repair. There are more than 30 subtypes; within each Limb Girdle Muscular Dystrophy (LGMD) subtype, the severity, age of onset, and features demonstrate a high degree of consistency.

An ENMC Consensus in 2017, classified Limb Girdle Muscular Dystrophy (LGMD) based on its inheritance pattern and clinical characteristics into two types: autosomal dominant (LGMD type 1), autosomal recessive (LGMD type 2). Dominant forms of LGMD have usually a slow course, while recessive form can have an early onset and fast progression, but a number of LGMD2 patients with adult-onset remain ambulant until late in life. The dominant forms are mostly associated with cardiac complications and breathing problems along with muscle wasting.

The DelveInsight Limb Girdle Muscular Dystrophy (LGMD) market report gives the thorough understanding of the LGMD by including details such as disease definition, symptoms, classification, causes, pathophysiology, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Limb Girdle Muscular Dystrophy (LGMD) in the US, Europe, and Japan.

Limb Girdle Muscular Dystrophy (LGMD) Epidemiology

The Limb Girdle Muscular Dystrophy (LGMD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Total Prevalence of Limb-Girdle Muscular Dystrophy, Type specific cases, Severity specific cases, Diagnosed population of Limb-Girdle Muscular Dystrophy] scenario of LGMD in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2017-2028.

As per Corrado Angelini et. Al. the prevalence of all Limb-Girdle Muscular Dystrophy (LGMDs) types ranges from 4-7 per 100,000, depending on the geographical and ethnic origin. Large studies have found that in the specific areas i.e. south Europe, calpainopathy is the most prevalent form, while in Northern Europe calpainopathy can be unfrequent; but LGMD 2I is common. A large proportion of recessive LGMD cases is due to dysferlinopathy, sarcoglycanopathies.

According to National Organization for Rare Disorders, LGMD affects males and females in equal numbers. The prevalence of LGMD is unknown, but estimates range from one in 14,500 to one in 123,000. The age of onset can vary greatly even among individuals of the same family. The relative frequencies of the different types of LGMD vary from population to population.

Limb Girdle Muscular Dystrophy (LGMD) Drug Chapters

This segment of the Limb Girdle Muscular Dystrophy (LGMD) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

At present, there is no cure and no FDA approved therapies for the treatment of Limb-Girdle Muscular Dystrophy (LGMD), current research is mostly focused on the use of novel gene therapies in order to treat the underlying genetic changes.

Major pharmaceutical companies, such as Myonexus Therapeutics (MYO-101, MYO-102) and aTyr Pharma (ATYR1940), etc. are involved in the development of novel therapies for the treatment of Limb Girdle Muscular Dystrophy (LGMD).

Limb Girdle Muscular Dystrophy (LGMD) Market Outlook

The Limb Girdle Muscular Dystrophy (LGMD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The market of Limb Girdle Muscular Dystrophy (LGMD) in 7MM is expected to change from the study period 2017-2028.

Limb Girdle Muscular Dystrophy (LGMD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Limb Girdle Muscular Dystrophy (LGMD) Report Insights

- Patient Population

- Therapeutic Approaches

- Pipeline Analysis

- Market Size and Trends

- Market Opportunities

- Impact of upcoming Therapies

Limb Girdle Muscular Dystrophy (LGMD) Report Key Strengths

- 10 Years Forecast

- 7MM Coverage

- Epidemiology Segmentation

- Key Cross Competition

- Highly Analyzed Market

- Drugs Uptake

Limb Girdle Muscular Dystrophy (LGMD) Report Assessment

- Current Treatment Practices

- Unmet Needs

- Pipeline Product Profiles

- Market Attractiveness

- Market Drivers and Barriers

Key Benefits

- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Limb Girdle Muscular Dystrophy (LGMD) market

- Organize sales and marketing efforts by identifying the best opportunities for Limb Girdle Muscular Dystrophy (LGMD) market

- To understand the future market competition in the Limb Girdle Muscular Dystrophy (LGMD) market.

Limb Girdle Muscular Dystrophy (LGMD) Market Insights, Epidemiology and Market Forecast - 2028

Table of Contents

1. Report Introduction
2. Limb-Girdle Muscular Dystrophy (LGMD) Market Overview at a Glance
2.1. Global Market Size of Limb-Girdle Muscular Dystrophy (LGMD) in 2018
2.2. Global Market Size of Limb-Girdle Muscular Dystrophy (LGMD) in 2028
3. Disease Background and Overview: Limb-Girdle Muscular Dystrophy (LGMD)
3.1. Introduction
3.2. Causes
3.3. Types
3.4. Pathophysiology
3.5. Symptoms
3.6. Risk Factor
3.7. Diagnosis
4. Assumptions and Caveats
4.1. Limb-Girdle Muscular Dystrophy (LGMD) Geography Wise Prevalent Cases
4.1.1. 7MM Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.1.2. Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.1.3. Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.1.4. Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.2. United States
4.2.1. Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.2.2. Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.2.3. Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.2.4. Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.3. EU-5
4.4. Germany
4.4.1. Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.4.2. Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.4.3. Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.4.4. Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.5. Italy
4.5.1. Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.5.2. Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.5.3. Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.5.4. Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.6. Spain
4.6.1. Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.6.2. Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.6.3. Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.6.4. Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.7. France
4.7.1. Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.7.2. Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.7.3. Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.7.4. Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.8. United Kingdom
4.8.1. Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.8.2. Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.8.3. Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.8.4. Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.9. Japan
4.9.1. Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.9.2. Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.9.3. Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
4.9.4. Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2028)
5. Treatment Practices
5.1. Treatment Algorithm
5.2. Treatment Guidelines
6. Key Emerging Therapies
6.1. Key Cross Competition
6.2. MYO-101 : Myonexus Therapeutics
6.2.1. Regulatory Milestones
6.2.2. Clinical Development
6.2.3. Product Profile
6.2.4. Clinical Pipeline Activity
6.2.5. Ongoing Trials Information
6.2.6. Clinical Trial by Phase
6.3. ATYR1940 : aTyr Pharma
6.3.1. Regulatory Milestones
6.3.2. Clinical Development
6.3.3. Product Profile
6.3.4. Clinical Pipeline Activity
6.3.5. Ongoing Trials Information
6.3.6. Clinical Trial by Phase
To be continued in the report…
6.4. Current Unmet needs
7. Limb-Girdle Muscular Dystrophy (LGMD) Market Size
7.1. Key Findings
7.2. Total 7MM Limb-Girdle Muscular Dystrophy (LGMD) Market Analysis
7.3. Overview of Total Limb-Girdle Muscular Dystrophy (LGMD) Market
7.4. 7MM Limb-Girdle Muscular Dystrophy (LGMD): Country-Wise Market Analysis
7.4.1. United States
7.4.1.1. Total Market Size of Limb-Girdle Muscular Dystrophy (LGMD)
7.4.1.2. Market Size of Limb-Girdle Muscular Dystrophy (LGMD) by Therapies
7.4.2. Germany
7.4.2.1. Total Market Size of Limb-Girdle Muscular Dystrophy (LGMD)
7.4.2.2. Market Size of Limb-Girdle Muscular Dystrophy (LGMD) by Therapies
7.4.3. France
7.4.3.1. Total Market Size of Limb-Girdle Muscular Dystrophy (LGMD)
7.4.3.2. Market Size of Limb-Girdle Muscular Dystrophy (LGMD) by Therapies
7.4.4. United Kingdom
7.4.4.1. Total Market Size of Limb-Girdle Muscular Dystrophy (LGMD)
7.4.4.2. Market Size of Limb-Girdle Muscular Dystrophy (LGMD) by Therapies
7.4.5. Spain
7.4.5.1. Total Market Size of Limb-Girdle Muscular Dystrophy (LGMD)
7.4.5.2. Market Size of Limb-Girdle Muscular Dystrophy (LGMD) by Therapies
7.4.6. Italy
7.4.6.1. Total Market Size of Limb-Girdle Muscular Dystrophy (LGMD)
7.4.6.2. Market Size of Limb-Girdle Muscular Dystrophy (LGMD) by Therapies
7.4.7. Japan
7.4.7.1. Total Market Size of Limb-Girdle Muscular Dystrophy (LGMD)
7.4.7.2. Market Size of Limb-Girdle Muscular Dystrophy (LGMD) by Therapies
8. Market Drivers
9. Market Barriers
10. Report Methodology
10.1. Sources Used
11. DelveInsight Capabilities
12. Disclaimer
13. About DelveInsight

List of Tables

Table 1 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in the US (2017-2028)
Table 2 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in the US (2017-2028)
Table 3 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in the US (2017-2028)
Table 4 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in the US (2017-2028)
Table 5 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Germany (2017-2028)
Table 6 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Germany (2017-2028)
Table 7 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Germany (2017-2028)
Table 8 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Germany (2017-2028)
Table 9 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Italy (2017-2028)
Table 10 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Italy (2017-2028)
Table 11 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Italy (2017-2028)
Table 12 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Italy (2017-2028)
Table 13 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Spain (2017-2028)
Table 14 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Spain (2017-2028)
Table 15 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Spain (2017-2028)
Table 16 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Spain (2017-2028)
Table 17 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in France (2017-2028)
Table 18 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in France (2017-2028)
Table 19 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in France (2017-2028)
Table 20 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in France (2017-2028)
Table 21 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in the UK (2017-2028)
Table 22 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in the UK (2017-2028)
Table 23 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in the UK (2017-2028)
Table 24 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in the UK (2017-2028)
Table 25 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Japan (2017-2028)
Table 26 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Japan (2017-2028)
Table 27 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Japan (2017-2028)
Table 28 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Japan (2017-2028)
Table 29 Treatment of manifestations
Table 30 Recommendations for practice
Table 31 Treatment for organ specific complications of Limb-Girdle Muscular Dystrophy (LGMD)
Table 32 MYO-101, Clinical Trials by Recruitment status, 2018
Table 33 MYO-101, Clinical Trials by Zone, 2018
Table 34 ATYR1940, Clinical Trials by Recruitment status, 2018
Table 35 ATYR1940, Clinical Trials by Zone, 2018
Table 36 Total 7 Major Market Size in USD, Million (2017-2028)
Table 37 Region wise Market Size in USD, Million (2017-2028)
Table 38 7MM-Market Size by Therapy in USD, Million (2017-2028)
Table 39 United States Market Size in USD, Million (2017-2028)
Table 40 United States Market Size by Therapy in USD, Million (2017-2028)
Table 41 Germany Market Size in USD, Million (2017-2028)
Table 42 Germany Market Size by Therapy in USD, Million (2017-2028)
Table 43 France Market Size in USD, Million (2017-2028)
Table 44 France Market Size by Therapy in USD, Million (2017-2028)
Table 45 United Kingdom Market Size in USD, Million (2017-2028)
Table 46 United Kingdom Market Size by Therapy in USD, Million (2017-2028)
Table 47 Spain Market Size in USD, Million (2017-2028)
Table 48 Spain Market Size by Therapy in USD, Million (2017-2028)
Table 49 Italy Market Size in USD, Million (2017-2028)
Table 50 Italy Market Size by Therapy in USD, Million (2017-2028)
Table 51 Japan Market Size in USD, Million (2017-2028)
Table 52 Japan Market Size by Therapy in USD, Million (2017-2028)

List of Figures

Figure 1 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in the US (2017-2028)
Figure 2 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in the US (2017-2028)
Figure 3 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in the US (2017-2028)
Figure 4 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in the US (2017-2028)
Figure 5 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Germany (2017-2028)
Figure 6 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Germany (2017-2028)
Figure 7 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Germany (2017-2028)
Figure 8 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Germany (2017-2028)
Figure 9 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Italy (2017-2028)
Figure 10 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Italy (2017-2028)
Figure 11 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Italy (2017-2028)
Figure 12 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Italy (2017-2028)
Figure 13 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Spain (2017-2028)
Figure 14 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Spain (2017-2028)
Figure 15 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Spain (2017-2028)
Figure 16 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Spain (2017-2028)
Figure 17 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in France (2017-2028)
Figure 18 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in France (2017-2028)
Figure 19 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in France (2017-2028)
Figure 20 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in France (2017-2028)
Figure 21 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in the UK (2017-2028)
Figure 22 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in the UK (2017-2028)
Figure 23 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in the UK (2017-2028)
Figure 24 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in the UK (2017-2028)
Figure 25 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Japan (2017-2028)
Figure 26 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Japan (2017-2028)
Figure 27 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Japan (2017-2028)
Figure 28 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Japan (2017-2028)
Figure 29 Treatment of manifestations
Figure 30 Recommendations for practice
Figure 31 Treatment for organ specific complications of Limb-Girdle Muscular Dystrophy (LGMD)
Figure 32 MYO-101, Clinical Trials by Recruitment status, 2018
Figure 33 MYO-101, Clinical Trials by Zone, 2018
Figure 34 ATYR1940, Clinical Trials by Recruitment status, 2018
Figure 35 ATYR1940, Clinical Trials by Zone, 2018
Figure 36 Total 7 Major Market Size in USD, Million (2017-2028)
Figure 37 Region wise Market Size in USD, Million (2017-2028)
Figure 38 7MM-Market Size by Therapy in USD, Million (2017-2028)
Figure 39 United States Market Size in USD, Million (2017-2028)
Figure 40 United States Market Size by Therapy in USD, Million (2017-2028)
Figure 41 Germany Market Size in USD, Million (2017-2028)
Figure 42 Germany Market Size by Therapy in USD, Million (2017-2028)
Figure 43 France Market Size in USD, Million (2017-2028)
Figure 44 France Market Size by Therapy in USD, Million (2017-2028)
Figure 45 United Kingdom Market Size in USD, Million (2017-2028)
Figure 46 United Kingdom Market Size by Therapy in USD, Million (2017-2028)
Figure 47 Spain Market Size in USD, Million (2017-2028)
Figure 48 Spain Market Size by Therapy in USD, Million (2017-2028)
Figure 49 Italy Market Size in USD, Million (2017-2028)
Figure 50 Italy Market Size by Therapy in USD, Million (2017-2028)
Figure 51 Japan Market Size in USD, Million (2017-2028)
Figure 52 Japan Market Size by Therapy in USD, Million (2017-2028)
  • Global Solubility Enhancement Excipients for OSDF Market Professional Survey 2019 by Manufacturers, Regions, Countries, Types and Applications, Forecast to 2024
    Published: 25-Apr-2019        Price: US 2900 Onwards        Pages: 142
    The Solubility Enhancement Excipients for OSDF market was valued at XX Million US$ in 2018 and is projected to reach XX Million US$ by 2024, at a CAGR of XX% during the forecast period. In this study, 2018 has been considered as the base year and 2019 to 2024 as the forecast period to estimate the market size for Solubility Enhancement Excipients for OSDF. Global Solubility Enhancement Excipients for OSDF industry market professional research 2014-2024, is a report which provides ......
  • Global (United States, European Union and China) Medical Tourniquets Market Research Report 2019-2025
    Published: 24-Apr-2019        Price: US 3280 Onwards        Pages: 110
    In 2019, the market size of Medical Tourniquets is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period. In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Medical Tourniquets. This report studies the global market size o......
  • Global Liver Health Supplements Market Size, Status and Forecast 2019-2025
    Published: 24-Apr-2019        Price: US 3900 Onwards        Pages: 93
    Liver is the largest internal organ in the body and it works as a garbage collector. Liver health and its functionality is important for healthily body function. In 2018, the global Liver Health Supplements market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. This report focuses on the global Liver Health Supplements status, future forecast, growth opportunity, key market and key players. The stud......
  • Global (United States, European Union and China) Postpartum Depression Treatment Market Research Report 2019-2025
    Published: 24-Apr-2019        Price: US 3280 Onwards        Pages: 118
    In 2019, the market size of Postpartum Depression Treatment is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period. In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Postpartum Depression Treatment. This report studies ......
  • Global (United States, European Union and China) Yersinia Diagnostics Market Research Report 2019-2025
    Published: 24-Apr-2019        Price: US 3280 Onwards        Pages: 114
    In 2019, the market size of Yersinia Diagnostics is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period. In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Yersinia Diagnostics. This report studies the global market size......
  • Global Industrial Hemp in Medical Market Insights, Forecast to 2025
    Published: 24-Apr-2019        Price: US 3900 Onwards        Pages: 116
    Industrial hemp is varieties of Cannabis sativa that have a tetrahydrocannabinol (THC) content generally below 0.35 percent. The global Industrial Hemp in Medical market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Industrial Hemp in Medical market based on company, product type, end user and key regions. This r......
  • Global Influenza Drugs and Vaccines Market Insights, Forecast to 2025
    Published: 24-Apr-2019        Price: US 3900 Onwards        Pages: 112
    The global Influenza Drugs and Vaccines market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Influenza Drugs and Vaccines market based on company, product type, end user and key regions. This report studies the global market size of Influenza Drugs and Vaccines in key regions like North America, Europe, Asia Pacific, Central & So......
  • Global (United States, European Union and China) Atrial Fibrillation Drugs Market Research Report 2019-2025
    Published: 24-Apr-2019        Price: US 3280 Onwards        Pages: 124
    In 2019, the market size of Atrial Fibrillation Drugs is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period. In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Atrial Fibrillation Drugs. This report studies the global m......
  • Global Artemether Market Insights, Forecast to 2025
    Published: 24-Apr-2019        Price: US 3900 Onwards        Pages: 119
    The global Artemether market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Artemether market based on company, product type, end user and key regions. This report studies the global market size of Artemether in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the c......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs